Zymenex A/S
- Country
- 🇩🇰Denmark
- Ownership
- Subsidiary
- Established
- 1998-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.zymenex.com
Evaluation of Long-term Efficacy of Treatment With Lamazym
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 18
- Registration Number
- NCT02478840
- Locations
- 🇩🇰
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01681940
- Locations
- 🇧🇪
Kinderneurologie Metabole Ziekten, UZ Brussel, Laarbeeklaan 101, Brussel, Belgium
🇩🇰Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
🇪🇸Servicio de Pediatría, Hospital Materno Infantil, Reina Sofía, Avda Menéndez Pidal sn, Córdoba, Spain
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
- First Posted Date
- 2012-09-10
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 25
- Registration Number
- NCT01681953
- Locations
- 🇩🇰
Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
🇫🇷Hôpital Femme Mère Enfant, Lyon, 59 boulevard Pinel, Bron, France
🇫🇷Hôpital Trousseau, Service de neuropédiatrie, Centre Référence des Maladies Lysosomales, 26 avenue du Docteur Arnold Netter, PARIS Cedex 12, France
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01285700
- Locations
- 🇩🇰
Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, Denmark
Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis
- First Posted Date
- 2010-12-30
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 10
- Registration Number
- NCT01268358
The Natural History of Infantile Globoid Cell Leukodystrophy
- Conditions
- Infantile Globoid Cell Leukodystrophy
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 6
- Registration Number
- NCT00983879
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, 4401 One Children's Hospital Drive,4401 Penn Avenue, Pittsburgh, Pennsylvania, United States
The Natural History of Alpha-Mannosidosis
- Conditions
- Alpha Mannosidosis
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 45
- Registration Number
- NCT00498420
- Locations
- 🇨🇿
Department of Pediatrics, Charles University, Prague, Czechia
🇩🇪University of Mainz, Mainz, Germany
🇳🇴Department of Medicine, University of Tromsoe, Tromsoe, Norway
Porphozym in the Treatment of Acute Attacks in AIP
- Conditions
- Acute Intermittent Porphyria
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-03-09
- Lead Sponsor
- Zymenex A/S
- Target Recruit Count
- 36
- Registration Number
- NCT00418795
- Locations
- 🇺🇸
Univercity Texas Medical Branch, Galveston, Texas, United States